Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,069 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo, Cohort 3 Clear all
Completed Phase 2 Interventional Results available

Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas

NCT02828111
View directory record Official record
Conditions
Basal Cell Carcinomas
Interventions
Patidegib, Vehicle gel
Drug
Lead sponsor
PellePharm, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 1Phase 2 Interventional

Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

NCT06863467
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Interventions
Intravenous Gemini, Intravenous placebo
Drug
Lead sponsor
Revelation Biosciences, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Chula Vista, California • La Mesa, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 16, 2026, 10:40 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity

NCT06842186
View directory record Official record
Conditions
Overweight and Obesity
Interventions
WVE-007
Drug
Lead sponsor
Wave Life Sciences USA, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Abemaciclib in Healthy Participants

NCT02677844
View directory record Official record
Conditions
Healthy
Interventions
Abemaciclib, Placebo, Loperamide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 1Phase 2 Interventional

Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

NCT04238793
View directory record Official record
Conditions
Neuropathic Pain From Lumbosacral Radiculopathy
Interventions
KLS-2031, Placebo
Drug · Other
Lead sponsor
Kolon Life Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 16, 2026, 10:40 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

MLN3126 Single Rising Dose Study

NCT02447458
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MLN3126, MLN3126 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects

NCT04680429
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RP7214, Placebo
Drug
Lead sponsor
Rhizen Pharmaceuticals SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Las Vegas, Nevada • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 16, 2026, 10:40 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia

NCT01566630
View directory record Official record
Conditions
Pre-eclampsia
Interventions
Placebo, RLX030
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Mobile, Alabama • Lexington, Kentucky • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

NCT04952545
View directory record Official record
Conditions
Healthy
Interventions
ALXN2050, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 16, 2026, 10:40 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

NCT07441395
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic
Interventions
Soquelitinib, Placebo
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects

NCT07809919
View directory record Official record
Conditions
Visceral Leishmaniasis, Chagas Disease
Interventions
LXE408, Placebo, Iohexol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

NCT04447469
View directory record Official record
Conditions
COVID
Interventions
mavrilimumab, Placebo
Drug · Other
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Industry
Eligibility
18 Years and older
Enrollment
814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 16, 2026, 10:40 AM EDT
Recruiting Phase 3 Interventional

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

NCT03808922
View directory record Official record
Conditions
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Interventions
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
Not listed
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
23
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model

NCT01965600
View directory record Official record
Conditions
Healthy
Interventions
PF-06282999, Placebo, LPS
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 40 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers

NCT02742779
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0310, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 16, 2026, 10:40 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

NCT06686654
View directory record Official record
Conditions
Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Interventions
Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
1,530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants

NCT06315335
View directory record Official record
Conditions
Healthy Participants
Interventions
UCB9741, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 16, 2026, 10:40 AM EDT
Terminated Phase 1 Interventional

Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer

NCT01790035
View directory record Official record
Conditions
Gastrointestinal Neoplasms
Interventions
LGG, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease

NCT04365218
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
MEDI8367, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

NCT04707313
View directory record Official record
Conditions
Obesity
Interventions
Placebo (Cohorts 1 and 2), PF-06882961 (Cohorts 1 and 2), Placebo (Cohort 3), PF-06882961 (Cohort 3)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
27
States / cities
Anniston, Alabama • Anaheim, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

NCT02207790
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 16, 2026, 10:40 AM EDT
Terminated Phase 1 Interventional

Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

NCT00529113
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Cancer
Interventions
Bardoxolone methyl, Gemcitabine, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

NCT03119649
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
GLPG2222 50 mg, GLPG2222 100 mg, Placebo, GLPG2222 200 mg, GLPG2222 400 mg
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years to 99 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
7
States / cities
Chatom, Alabama • Little Rock, Arkansas • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

NCT06086613
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
AGA2115, Placebo
Drug
Lead sponsor
Angitia Incorporated Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lake Forest, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 16, 2026, 10:40 AM EDT